Sensorion SA
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin def…
Biotechnology
FR, Montpellier [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
Metric | Q4 | Q2 | Δ in % | |
---|---|---|---|---|
EV/EBITDA | -8.72 | -7.02 | -6.46 | |
Graham Fair Price | 33.50 | 0.61 | 0.46 | |
PEG | 0.00 | 0.00 | 0.00 | |
Price/Book | -10.58 | 2.16 | 2.42 | |
Price/Cash Flow | -102.53 | -14.62 | -7.22 | |
Prices/Earnings | -57.84 | -3.24 | -2.06 | |
Price/Sales | 115.48 | 57.51 | 26.69 | |
Price/FCF | -102.53 | -14.62 | -7.22 | |
Naive Interpretation | member |
01 - Valuation ·
Weak
Fundamentals
Profitability
Metric | Q4 | Q2 | Δ in % | |
---|---|---|---|---|
Gross Profit Margin | -2.68 | 0.82 | 0.84 | |
Operating Margin | -99.13 | 0.04 | -4.36 | |
ROA | 34.91 | -0.14 | -0.21 | |
ROE | -0.29 | -0.17 | 43.35 | |
ROIC | -0.30 | < 0.005 | -99.53 | |
Naive Interpretation | member |
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
Metric | Q4 | Q2 | Δ in % | |
---|---|---|---|---|
Debt QOQ | 0.00 | 0.00 | 0.00 | |
Dividends QOQ | 0.00 | 0.00 | 0.00 | |
EBIT QOQ | 0.00 | 0.00 | 0.00 | |
EPS QOQ | 0.00 | 0.00 | 0.00 | |
FCF QOQ | 0.00 | 0.00 | 0.00 | |
Revenue QOQ | 0.00 | 0.00 | 0.00 | |
Naive Interpretation | member |
03 - Financial Growth ·
Not Interpreted
Fundamentals
Leverage & Liquidity
Metric | Q4 | Q2 | Δ in % | |
---|---|---|---|---|
Assets Turnover | n.A. | n.A. | n.A. | |
Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
Days Sales Outstanding (DSO) | 159.00 | 246.60 | 55.09 | |
Inventory Turnover | 0.00 | 0.00 | 0.00 | |
Debt/Capitalization | 0.07 | 0.02 | -70.22 | |
Quick Ratio | 4.12 | 6.91 | 67.99 | |
Naive Interpretation | member |
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
Metric | Q4 | Q2 | Δ in % | |
---|---|---|---|---|
Book Value | 0.18 | 0.32 | 77.37 | |
Cash | 0.20 | 0.61 | 210.86 | |
Capex | < 0.005 | < 0.005 | -38.76 | |
Free Cash Flow | -0.06 | -0.05 | 21.69 | |
Revenue | 0.02 | 0.01 | -26.40 | |
Naive Interpretation | member |
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad